Rewind Therapeutics Secures 15.2 M EURO to Develop Novel Remyelination Therapies
(4 months ago)
LEUVEN, Belgium: Rewind Therapeutics, a privately held Belgian biotech company, today announced the completion of a Euro15.2 million Series A financing to develop novel re-myelinating therapies for patients suffering from Multiple Sclerosis and other myelin-related diseases.
The round was led by life science investors Boehringer Ingelheim Venture Fund (BIVF), Merck Ventures BV (MV) and Participatiemaatschappij Vlaanderen (PMV), together with KU Leuven's Centre for Drug Design and Discovery (CD3) and KU Leuven Gemma Frisius Fonds (GFF).
The company will use the proceeds of the €15.2million series A round to bring their proprietary first small molecule product to the clinic and to further expand their pipeline of novel drug candidates targeting myelin disorders.
Rewind Therapeutics is founded by CD3 (Leuven, Belgium) and Axxam S.p.A. (Milano, Italy). In close collaboration with both organizations and a world-class academic network, Rewind Therapeutics aspires to advance innovative first-in-class therapies for myelin-related diseases into fast track clinical application.